Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals develops and commercializes products for central nervous system diseases. Commercial products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER. Product candidates include SPN-830, SPN-817, SPN-820, SPN-443, SPN-446, and SPN-448. The company markets products through wholesalers, specialty pharmacies, and distributors. It was incorporated in 2005 and is headquartered in Rockville, Maryland.

Overview

Sector

Pharmaceutical

Target Price

2.3 USD

Current Price

48.1 USD

Potential

-95%

Strengths

Price to book ratio (2.63) is lower than the sector mean (733.70).
The company has low debt. Net Debt to EBITDA Ratio is -1.29 and it is lower than the sector mean.

Weaknesses

With a depreciation Potential of -95.33%, based on our fundamental analysis, it suggests the stock may be overvalued.
Analysts expect revenues to decline in the coming year.
The company have lower returns than the sector in which it operates. ROIC (4.29%) is significantly lower than the sector mean (14.71%).
EBITDA Margin (9.45%) appears relatively low.

Indicator	Value
PER	100.0
EV/EBITDA	39.3
Price/Free Cash Flow'	60.0
ROIC	4.3%
Net Debt/EBITDA	-1.3

Supernus Pharmaceuticals, Inc.

Overview

Strengths

Weaknesses

Key Financial Data